Drug: Rucaparib (Rubraca, Clovis)
Status: Approved for women with advanced ovarian cancer who have been treated with 2 or more chemotherapies and whose tumors have a specific genetic mutation (deleterious BRCA) as identified by an FDA-approved companion diagnostic test
Significant Data:
- First and only poly(ADP-ribose) polymerase inhibitor approved for this indication in the US
- Approval was based on 2, single-arm clinical trials involving 106 participants with BRCA-mutated advanced ovarian cancer